You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Generics of old GLP-1s could make new versions cheaper
Two of the oldest GLP-1 drugs have gone generic, and that could help Medicare bargain for lower prices on Ozempic and other brand-name versions of semaglutide, right as the public health insurance program considers covering them for weight loss.
It’s confusing to keep track of the developments related to GLP-1s and how generics could impact the price of the current blockbusters.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
